One-hundred-twenty female patients affected by non-metastatic HER2 positive breast cancer referring to the Oncology Department of our institute and receiving Trastuzumab treatment between 2014 and 2021 were enrolled in the present study. Here, ERBB2 is linked to breast cancer.